Developing nanoparticles to deliver HIV-1 vaccines
Nanoparticle-based development for HIV-1 biomolecule delivery
['FUNDING_OTHER'] · INTERNATIONAL AIDS VACCINE INITIATIVE · NIH-10863796
This study is working on tiny particles that can help deliver better vaccines for HIV, aiming to create safer and more effective options to help prevent HIV infection for people at risk.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INTERNATIONAL AIDS VACCINE INITIATIVE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10863796 on ClinicalTrials.gov |
What this research studies
This research focuses on creating nanoparticles that can effectively deliver biomolecules for HIV-1 vaccine development. By utilizing advanced techniques in chemistry and molecular biology, the project aims to enhance the delivery and efficacy of potential vaccines against HIV. The approach includes process development and analytical characterization to ensure that the vaccines can progress through clinical trials safely and effectively. Patients may benefit from improved vaccine options that could lead to better prevention of HIV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for HIV infection or those interested in participating in HIV vaccine trials.
Not a fit: Patients who are already living with HIV or those who are not at risk for HIV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly reduce the risk of HIV infection.
How similar studies have performed: Other research has shown promise in using nanoparticle delivery systems for vaccines, indicating a potential for success in this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- INTERNATIONAL AIDS VACCINE INITIATIVE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HASSELL, THOMAS — INTERNATIONAL AIDS VACCINE INITIATIVE
- Study coordinator: HASSELL, THOMAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, HIV Infections, HTLV-III Infections, HTLV-III-LAV Infections